Infusion of Dexmedetomidine Versus Lidocaine in Management of Acute Postoperative Pain After Modified Radical Mastectomy

Launched by CAIRO UNIVERSITY · May 15, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how well two different medications—dexmedetomidine and lidocaine—work to manage pain after a surgical procedure called a modified radical mastectomy, which is often performed to treat breast cancer. Researchers want to see which medication is more effective in reducing acute postoperative pain, helping patients feel more comfortable after their surgery.

To participate in this study, women aged 18 to 65 who are scheduled for a modified radical mastectomy may be eligible if they are in generally good health and meet certain medical criteria. It’s important to note that individuals with specific health conditions, such as severe heart or kidney problems, or those currently using certain medications, may not be able to join. Participants can expect to receive one of the two medications during their surgery and will be monitored for pain management afterward. This trial is currently recruiting participants, which means they are looking for women who fit the eligibility criteria to join in and help advance understanding of pain management in surgical recovery.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Age from 18 to 65 years.
• • American Society of Anesthesiology (ASA) physical status II.
• • Body mass index (BMI) 18.5-35 kg/m2.
• • Scheduled for modified radical mastectomy.
• Exclusion Criteria:
• • Patient's refusal.
• • Contraindication to the use of local anesthetics.
• • Cardiovascular disease.
• • Significant renal/hepatic impairment
• • Insulin-dependent diabetes mellitus.
• • Central nervous system or psychiatric disease.
• • Use of opioids/steroids/clonidine/other α2 agonist/analgesics or any drugs acting on the central nervous system during the previous 2 weeks.
• • Drug/alcohol abuse.
• • Inability to comprehend the pain assessment scale.